Quotient Sciences, a drug development and manufacturing accelerator with facilities in the UK and the US, has acquired Arcinova, a UK-based multiservice contract development and manufacturing organization (CDMO).
Lonza will provide manufacturing for Alector’s Phase I drug candidates for neurodegenerative diseases from its Switzerland site, which is expected to be operational by mid-2020.
As the Pfizer-AstraZeneca mega-merger seems to be pushing towards a deal, early phase CROs may be the first to suffer for a short period of time directly after the merger is complete, some say, while others don't seem to think there will be much...
Italian CRO Centro Ricerche Cliniche di Verona (CRC) has become the first firm to be awarded a new early phase accreditation from the European CROs Federation (EUCROF).
After almost two years of lagging early phase clinical research work, it seems some CROs are now seeing an uptick in specialized trials that require more scientific expertise.
Charles River Laboratories (CRL) continued to experience low demand for preclinical services in Q3, while Covance's early-phase business saw revenue growth.
Parexel has opened a 40 bed early phase clinical trial unit in South Africa, increasing its Phase I capabilities in the country and adding to its patient recruitment focused SuperSites network.
Parexel has entered into an alliance with Mortara Instrument to bolster its early phase cardiac safety capabilities and improve the assesment of new compounds.